Kalvista Pharmaceuticals, INC Schedule 13G passive stakes

KalVista Pharmaceuticals, Inc. has filed an amendment to its Schedule 13G, reporting on beneficial ownership as of June 30, 2026.

SilverArc Capital Management, LLC and Devesh Gandhi have reported a 0% ownership stake in Kalvista Pharmaceuticals, Inc., indicating a full divestment of their Class A Common Stock.

SilverArc Capital Management, LLC and Devesh Gandhi report zero beneficial ownership of Kalvista Pharmaceuticals, Inc. Class A Common Stock as of June 30, 2026.

Glazer Capital, LLC and Paul J. Glazer have filed a Schedule 13G disclosing that their beneficial ownership in KalVista Pharmaceuticals has fallen below the 5% threshold.

SilverArc Capital Management, LLC and Devesh Gandhi have reported beneficial ownership of 5.6% of KalVista Pharmaceuticals Inc.'s Class A Common Stock as of March 31, 2026.

Millennium Management LLC and affiliated entities have filed an amended Schedule 13G, disclosing their beneficial ownership in KalVista Pharmaceuticals, Inc.

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, filed an amended Schedule 13G to correct their beneficial ownership of KalVista Pharmaceuticals, Inc. common stock, now reporting a 5.5% stake.

Point72 Asset Management, along with its affiliates and Steven A. Cohen, has disclosed a 4.9% beneficial ownership stake in KalVista Pharmaceuticals, Inc.

Millennium Management LLC and affiliated entities have reported a combined 5.9% passive beneficial ownership in KalVista Pharmaceuticals, Inc.

Vestal Point Capital, LP and Ryan Wilder have reported a 1.5% beneficial ownership stake in KalVista Pharmaceuticals, Inc., holding 750,000 shares.

Millennium Management LLC and affiliates have reported a 5.0% beneficial ownership stake in KalVista Pharmaceuticals, Inc. common stock.

Tang Capital Management and affiliated entities, including Kevin Tang, have filed an amended Schedule 13G disclosing a collective beneficial ownership of 9.9% in KalVista Pharmaceuticals, Inc.

Capital World Investors, a division of Capital Research and Management Company, has filed an amended Schedule 13G disclosing a 6.4% beneficial ownership stake in KalVista Pharmaceuticals, Inc.

A group of Venrock Healthcare Capital Partners entities and individuals have reaffirmed their passive beneficial ownership of 10.1% of KalVista Pharmaceuticals, Inc.'s common stock.